tada

There are some posts on IV talking about the amount of cash that biotech's are sitting on. Perhaps with the failure of CEPT inhibitors some of the BPs will take a close look at RVX. 208 is directed at unmet needs and is may represent an entire new approach to medicine.

Perhaps Don will pull out the ace. Well know soon enough.

GLTA

Toinv